Molecular signatures in ductal carcinoma in situ (DCIS): A systematic review and meta-analysis
D Ouattara, C Mathelin, T Özmen, M Lodi - Journal of Clinical Medicine, 2023 - mdpi.com
Context: Adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) for ductal
carcinoma in situ (DCIS) is debated as benefits are inconstant. Molecular signatures for …
carcinoma in situ (DCIS) is debated as benefits are inconstant. Molecular signatures for …
Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS …
F Wärnberg, P Karlsson, E Holmberg, K Sandelin… - Cancers, 2021 - mdpi.com
Simple Summary Despite clinical advancements in the diagnosis and treatment of DCIS,
tailoring individual treatment for women diagnosed with DCIS remains an unmet clinical …
tailoring individual treatment for women diagnosed with DCIS remains an unmet clinical …
Analyzing precision medicine utilization with real-world data: a scoping review
MP Douglas, A Kumar - Journal of Personalized Medicine, 2022 - mdpi.com
Precision medicine (PM), specifically genetic-based testing, is currently used in over
140,000 individual tests to inform the clinical management of disease. Though several …
140,000 individual tests to inform the clinical management of disease. Though several …
A long lost key opens an ancient lock: Drosophila Myb causes a synthetic multivulval phenotype in nematodes
PJ Vorster, P Goetsch, TU Wijeratne, KZ Guiley… - Biology …, 2020 - journals.biologists.com
The five-protein MuvB core complex is highly conserved in animals. This nuclear complex
interacts with RB-family tumor suppressor proteins and E2F-DP transcription factors to form …
interacts with RB-family tumor suppressor proteins and E2F-DP transcription factors to form …
Novel markers in breast pathology
DJ Dabbs, RS Huang, JS Ross - Histopathology, 2023 - Wiley Online Library
Breast pathology is an ever‐expanding database of information which includes markers, or
biomarkers, that detect or help treat the disease as prognostic or predictive information. This …
biomarkers, that detect or help treat the disease as prognostic or predictive information. This …
Effect of the Ductal Carcinoma In Situ Margin Consensus Guideline Implementation on Re-Excision Rates, Satisfaction, and Cost
N Bhutiani, MM Holland, MK Mercer… - Annals of Surgical …, 2021 - Springer
Introduction The 2016 consensus guideline on margins for breast-conserving surgery (BCS)
with whole-breast irradiation (WBI) for ductal carcinoma in situ (DCIS) recommended 2 mm …
with whole-breast irradiation (WBI) for ductal carcinoma in situ (DCIS) recommended 2 mm …
[PDF][PDF] Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical …
F Wärnberg, P Karlsson, E Holmberg, K Sandelin… - 2021 - minerva-access.unimelb.edu.au
Prediction of radiotherapy (RT) benefit after breast-conserving surgery (BCS) for DCIS is
crucial. The aim was to validate a biosignature, DCISionRT®, in the SweDCIS randomized …
crucial. The aim was to validate a biosignature, DCISionRT®, in the SweDCIS randomized …
[PDF][PDF] Carcinoma ductal in situ, fatores de prognóstico e individualização do tratamento
ACPDS Pereira - 2021 - repositorio-aberto.up.pt
Introdução: Com o advento do rastreio, a incidência de Carcinoma Ductal In Situ (CDIS)
aumentou 6x a nível mundial, correspondendo a 25% dos diagnósticos de cancro da mama …
aumentou 6x a nível mundial, correspondendo a 25% dos diagnósticos de cancro da mama …
[HTML][HTML] Using Biology to More Effectively Diagnose and Manage Breast Cancer David M. Hyams, MD, FACS
DR HYAMS, DR INTERVIEWS - desertsurgicaloncology.com
Breast screening has been widely adopted in the United States with nearly 65% of the
eligible population undergoing examination. Evolving technologic advancements have also …
eligible population undergoing examination. Evolving technologic advancements have also …